Literature DB >> 1463039

Criteria to detect minimal expressivity within families with autosomal dominant aniridia.

H A Mintz-Hittner1, R E Ferrell, L A Lyons, F L Kretzer.   

Abstract

Autosomal dominant aniridia with complete penetrance without Wilms' tumor in five generations with 27 affected family members has been reassigned from chromosome 2p25 to chromosome 11p13. Clinically, aniridia was obvious in affected individuals with variable expressivity when they had rudimentary iris stumps, typical or atypical iris colobomata, or round, eccentric pupils. However, iris and retinal fluorescein angiography was required to detect abnormal vascular remodeling that resulted in incomplete iris collarettes and decreased retinal foveal avascular zones in 27 family members at risk with round, central pupils. These angiograms distinguished five affected and 22 unaffected individuals, and were the critical criteria required to detect minimal expressivity of aniridia in family members with round, central pupils.

Entities:  

Mesh:

Year:  1992        PMID: 1463039     DOI: 10.1016/s0002-9394(14)74048-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

Review 1.  Congenital iris ectropion as an indicator of variant aniridia.

Authors:  C Willcock; J Grigg; M Wilson; P Tam; F Billson; R Jamieson
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

2.  Genotype-phenotype correlation of PAX6 gene mutations in aniridia.

Authors:  Tadashi Yokoi; Sachiko Nishina; Maki Fukami; Tsutomu Ogata; Katsuhiro Hosono; Yoshihiro Hotta; Noriyuki Azuma
Journal:  Hum Genome Var       Date:  2016-02-11

3.  Molecular analysis of the PAX6 gene in Mexican patients with congenital aniridia: report of four novel mutations.

Authors:  Camilo E Villarroel; Cristina Villanueva-Mendoza; Lorena Orozco; Miguel Angel Alcántara-Ortigoza; Diana F Jiménez; Juan C Ordaz; Ariadna González-del Angel
Journal:  Mol Vis       Date:  2008-09-08       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.